Table 1

Three prognostic models of AL amyloidosis [12].

Prognostic model	Criteria	Survival
Mayo model 2004 [16]	TnT<0.035 μg/L	Stage 1-median 26.4 mo
	NT-pro-BNP<332 ng/L	Stage 2- median 10.5 mo
	BNP<81 ng/L	Stage 3- median 3.5 mo
	TnI<0.1 μg/L	Stage 3- median 3.5 mo
Mayo model 2012 [17]	TnT<0.025 ng/mL	Stage 1- median 94.1 mo
	NT-pro-BNP<1,800 pg/mL	Stage 2- median 40.3 mo
	Serum dFLC<180 mg/dL	Stage 3- median 14 mo
	BNP<400 ng/L	Stage 4- median 5.8 mo
	TnI- No data	Stage 4- median 5.8 mo
European model 2015 [18]	TnT<0.035 ng/mL	Stage 1- no death cases
	NT-pro-BNP<332 pg/mL	Stage 2- 3 yr 52%
	BNP<81 ng/L	Stage 3a- 3 yr 55%
	TnI<0.1 μg/L	Stage 3b- 3 yr 19%
	*Mayo 2004 stage 3 has been subclassified based on NT-pro-BNP<8,500 pg/mL	Stage 3b- 3 yr 19%
Boston university score 2019 [19]	TnT<0.1 ng/mL	Stage 1- median not reached
	BNP<81 pg/mL	Stage 2- median 9.4 yr
		Stage 3a- median 4.3 yr
		Stage 3b- median 1 yr